Developer docs
API playgroundTry for free, no card

Search company profiles

LDPath

Full company profile

uuid002rv5k

Namestring
LDPath
Legal namestring
LDPath
Websiteurl
ldpath.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

LDPath is a UK-based digital pathology reporting service founded in 2011, headquartered in Chichester with operations in London, and operating as a subsidiary of Source BioScience following a 2021 acquisition for £18.5 million. The company provides histopathology reporting services to 24 NHS trusts and 450+ private clinicians and clinics, utilizing a network of approximately 140 specialist consultant pathologists (over 100 of whom are validated on Whole Slide Imaging for primary diagnosis). LDPath was the first UK pathology provider to integrate whole slide imaging into primary reporting (2014) and the first to deploy clinical-grade AI for cancer detection through a 2020 partnership with Ibex Medical Analytics (CE-Marked Galen Prostate solution), and has accumulated over 100TB of digital pathology slides — described as the largest such library in the UK.

The company's core technology stack combines a proprietary, pathologist-designed LIMS application with whole slide imaging infrastructure, NHS HSCN connectivity, and AI-powered diagnostic modules, supporting a 1–2 day histology report turnaround with 94% of cases reported within 72 hours (sustained since 2014). Service modules include NHS Pathology Services, Private Practice Services, AI-Powered Diagnostics (Ibex Galen Prostate), Diagnostic Audits, and standalone Whole Slide Imaging scanning. The platform is held together by UKAS, ISO 9001, ISO 15189, CQC, and NHS Digital DSP Toolkit accreditations, plus sole registration in the National NHS Procurement Directory.

LDPath generates revenue through multi-year, flat-fee service contracts with NHS trusts and private practices on a per-case subscription basis, supplemented by professional services revenue from AI diagnostic workflows, standalone WSI scanning, and independent diagnostic audits. The go-to-market motion is enterprise field sales via dedicated NHS and Private Practice department managers supported by a UK-wide medical courier specimen collection network. International operations have been established via LDPath India and LDPath Dubai, extending digital pathology services into South Asian and Middle Eastern markets.

Short descriptiontext

LDPath is a UK-based digital pathology reporting service, owned by Source BioScience, providing whole slide imaging and AI-assisted histopathology to 24 NHS trusts and 450+ private clinicians via a network of 140 specialist pathologists.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital pathology services, histopathology reporting, whole slide imaging, AI cancer diagnostics, NHS pathology services
Industry4 codes
PRIMARYHLAGAFAI
Pathology & Histopathology Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLACAMAJ
Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
NAICS code1 code
  • Diagnostic Imaging Centers621512
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Digital Pathology Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Histopathology Reporting Services
TypeSubscription Recurring
Description

LDPath provides rapid histopathology reporting by specialist pathologists to NHS trusts and private practices. Services include specimen pickup, processing, diagnosis, and secure web-based report delivery. Turnaround time of 1-2 days for histology reports.

secure.ldpath.com
2AI Diagnostic Services
TypeProfessional Services
Description

AI-powered cancer detection services including primary reporting of prostate biopsies with AI algorithm review, 24-hour screening services, and UKAS annual audit services.

ldpath.com
3Whole Slide Imaging Scanning Services
TypeProfessional Services
Description

Standalone scanning service where client slides are digitized onto removable storage device or hosted in secure image cloud. Also includes MDT and second opinion arrangement services.

ldpath.com
4Diagnostic Audits
TypeProfessional Services
Description

Independent Investigative Audits and Duty of Care Reviews following Royal College of Pathologists guidelines, providing qualitative and quantitative summary documents for NHS trusts.

ldpath.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Pricing details1 tier
1Flat fee structure covering all services
ModelOtherBilling cadenceMulti-year contract
Notes

Flat fee structure including special stains, immunocytochemistry, courier and billing. Made-to-measure fee structure adapted to individual practice requirements. Regular practice reviews to ensure tailored service.

secure.ldpath.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

LDPath provides digital histopathology reporting services to NHS hospital trusts and private practices, combining whole slide imaging of glass slides with a bespoke Laboratory Information Management System (LIMS) for case tracking and report delivery. The service uses a network of specialist consultant pathologists to deliver rapid 1-2 day histology report turnaround, integrated second opinions, and AI-assisted cancer detection (via the Ibex Galen Prostate partnership) for prostate biopsy diagnosis.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

LDPath offers a unified digital pathology platform consisting of a core digital pathology reporting platform integrated with specialized service modules. The platform combines whole slide imaging digitization, a bespoke LIMS application for workflow management, and AI-powered diagnostics through the Ibex Galen Prostate partnership. Services are delivered through two main channels: NHS Pathology Services (serving 24 NHS Trusts with NHS LIMS integration) and Private Practice Pathology Services. Additional modules include Diagnostic Audits and standalone Whole Slide Imaging scanning services. The platform enables 1-2 day turnaround times with 94% of cases reported within 72 hours.

Product and service6 records
1LDPath Digital Pathology Reporting Platform
CategoryDigital Pathology Platform
Description

A cloud-based digital pathology reporting platform combining state-of-the-art histology digital imaging with a pathologist-designed reporting solution, providing the largest library of digital pathology images in the UK (over 100TB accumulated since 2014). Enables rapid 1-2 day histology report turnaround and on-demand second opinions from specialists.

2NHS Pathology Services
CategoryHistopathology Reporting
Description

Surgical pathology reporting service for NHS Trusts, providing histopathology expertise with IT connectivity and NHS LIMS integration via the Health and Social Care Network, currently serving 24 NHS Trusts across the UK.

3Private Practice Pathology Services
4AI-Powered Diagnostics (Ibex Galen Prostate)
CategoryAI-Assisted Diagnostics
Description

AI-integrated diagnostic workflow using Ibex Medical Analytics' CE-marked Galen Prostate solution for enhanced quality assurance in prostate cancer detection, including primary reporting with AI algorithm review, 24-hour screening services, and discrepancy alerts to pathologists.

5Diagnostic Audits
6Whole Slide Imaging Scanning Service
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-06-30
Description

LDPath partnered with Ibex Medical Analytics to integrate AI-powered cancer detection into their digital pathology workflow. This partnership deployed Ibex's CE-Marked Galen Prostate solution, enabling AI algorithm review of prostate biopsies alongside pathologist diagnosis. The integration provides quality assurance with discrepancy alerts and enables 24-hour prostate biopsy screening services. LDPath was the first UK pathology provider to integrate AI into digital pathology workflow.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

AI-driven pathology platform developing diagnostic and drug-development tools for histopathology. Comparable to LDPath's AI roadmap and a potential competitor for AI-enabled cancer detection contracts with NHS trusts and pharmaceutical sponsors.

TypeDirect peer
Description

Digital pathology platform providing remote histopathology reporting services to NHS trusts and private clients. Direct competitor to LDPath with similar cloud-based slide hosting, specialist pathologist network, and NHS-focused GTM motion.

TypeDirect peer
Description

Europe's largest medical diagnostics services provider with extensive histopathology capacity. Comparable to LDPath as a multi-country outsourced pathology provider serving both public health systems and private clients with digital workflow integration.

TypeDirect peer
Description

Parent company of LDPath following the 2021 £18.5M acquisition. Provides cellular pathology and genomic services that complement LDPath's digital pathology platform, with overlapping histopathology capabilities and shared customer relationships across NHS and pharmaceutical clients.

TypeEmerging player
Description

AI-powered cancer diagnostics developer and LDPath's technology partner for Galen Prostate. Comparable as a pathology-AI specialist; operates in the same clinical workflow with competing AI products that could be deployed by NHS trusts directly, bypassing LDPath.

TypeEmerging player
Description

Digital pathology software platform enabling AI-powered image analysis and pathology workflows. Comparable to LDPath's digital pathology platform layer; both sell into hospital pathology departments and biopharma, with overlapping AI/digital strategy.

TypeBroad incumbent
Description

Danaher-owned provider of digital pathology hardware, software (Aperio), and laboratory workflow solutions. Comparable to LDPath as an established digital pathology player, though operating more broadly across equipment, reagents, and software.

TypeBroad incumbent
Description

Global diagnostics incumbent offering the uPath digital pathology software platform alongside companion diagnostic AI. Comparable as an integrated digital pathology solution competing for the same NHS trust and hospital contracts as LDPath, with deeper R&D and distribution resources.

TypeEmerging player
Description

AI-native pathology company with FDA-authorized cancer detection products. Comparable to LDPath in AI-augmented cancer diagnostics and represents a potential competitor for AI procurement deals with NHS trusts and large hospital networks.

TypeDirect peer
Description

Major European clinical diagnostics and pathology provider offering histopathology services across multiple countries. Competes with LDPath in outsourced pathology reporting and operates a similar business model combining specialist pathologists with digital workflow.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LDPath

Digital Pathology Servicesldpath.com

LDPath is a UK-based digital pathology reporting service, owned by Source BioScience, providing whole slide imaging and AI-assisted histopathology to 24 NHS trusts and 450+ private clinicians via a network of 140 specialist pathologists.

What LDPath does

LDPath is a UK-based digital pathology reporting service founded in 2011, headquartered in Chichester with operations in London, and operating as a subsidiary of Source BioScience following a 2021 acquisition for £18.5 million. The company provides histopathology reporting services to 24 NHS trusts and 450+ private clinicians and clinics, utilizing a network of approximately 140 specialist consultant pathologists (over 100 of whom are validated on Whole Slide Imaging for primary diagnosis). LDPath was the first UK pathology provider to integrate whole slide imaging into primary reporting (2014) and the first to deploy clinical-grade AI for cancer detection through a 2020 partnership with Ibex Medical Analytics (CE-Marked Galen Prostate solution), and has accumulated over 100TB of digital pathology slides — described as the largest such library in the UK.

The company's core technology stack combines a proprietary, pathologist-designed LIMS application with whole slide imaging infrastructure, NHS HSCN connectivity, and AI-powered diagnostic modules, supporting a 1–2 day histology report turnaround with 94% of cases reported within 72 hours (sustained since 2014). Service modules include NHS Pathology Services, Private Practice Services, AI-Powered Diagnostics (Ibex Galen Prostate), Diagnostic Audits, and standalone Whole Slide Imaging scanning. The platform is held together by UKAS, ISO 9001, ISO 15189, CQC, and NHS Digital DSP Toolkit accreditations, plus sole registration in the National NHS Procurement Directory.

LDPath generates revenue through multi-year, flat-fee service contracts with NHS trusts and private practices on a per-case subscription basis, supplemented by professional services revenue from AI diagnostic workflows, standalone WSI scanning, and independent diagnostic audits. The go-to-market motion is enterprise field sales via dedicated NHS and Private Practice department managers supported by a UK-wide medical courier specimen collection network. International operations have been established via LDPath India and LDPath Dubai, extending digital pathology services into South Asian and Middle Eastern markets.

LDPath firmographics

Firmographics
Name
LDPath
Legal name
LDPath
Website
https://ldpath.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Short description
LDPath is a UK-based digital pathology reporting service, owned by Source BioScience, providing whole slide imaging and AI-assisted histopathology to 24 NHS trusts and 450+ private clinicians via a network of 140 specialist pathologists.
Ownership category
akta.pro rank

LDPath industry classification

Industry
Product category
Digital Pathology Services
NAICS
Diagnostic Imaging Centers (621512)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAFAI
Pathology & Histopathology Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLACAMAJ
Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)

Keywords

  • Digital pathology services
  • Histopathology reporting
  • Whole slide imaging
  • AI cancer diagnostics
  • NHS pathology services

Where LDPath is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

LDPath business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Histopathology Reporting Services: LDPath provides rapid histopathology reporting by specialist pathologists to NHS trusts and private practices. Services include specimen pickup, processing, diagnosis, and secure web-based report delivery. Turnaround time of 1-2 days for histology reports.
  2. AI Diagnostic Services: AI-powered cancer detection services including primary reporting of prostate biopsies with AI algorithm review, 24-hour screening services, and UKAS annual audit services.
  3. Whole Slide Imaging Scanning Services: Standalone scanning service where client slides are digitized onto removable storage device or hosted in secure image cloud. Also includes MDT and second opinion arrangement services.
  4. Diagnostic Audits: Independent Investigative Audits and Duty of Care Reviews following Royal College of Pathologists guidelines, providing qualitative and quantitative summary documents for NHS trusts.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractFlat fee structure covering all services

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

LDPath product offering

Product offering

Core offering

LDPath provides digital histopathology reporting services to NHS hospital trusts and private practices, combining whole slide imaging of glass slides with a bespoke Laboratory Information Management System (LIMS) for case tracking and report delivery. The service uses a network of specialist consultant pathologists to deliver rapid 1-2 day histology report turnaround, integrated second opinions, and AI-assisted cancer detection (via the Ibex Galen Prostate partnership) for prostate biopsy diagnosis.

Product overview

LDPath offers a unified digital pathology platform consisting of a core digital pathology reporting platform integrated with specialized service modules. The platform combines whole slide imaging digitization, a bespoke LIMS application for workflow management, and AI-powered diagnostics through the Ibex Galen Prostate partnership. Services are delivered through two main channels: NHS Pathology Services (serving 24 NHS Trusts with NHS LIMS integration) and Private Practice Pathology Services. Additional modules include Diagnostic Audits and standalone Whole Slide Imaging scanning services. The platform enables 1-2 day turnaround times with 94% of cases reported within 72 hours.

Differentiator

Problem solved

Functional benefit

Products and services

  • LDPath Digital Pathology Reporting Platform A cloud-based digital pathology reporting platform combining state-of-the-art histology digital imaging with a pathologist-designed reporting solution, providing the largest library of digital pathology images in the UK (over 100TB accumulated since 2014). Enables rapid 1-2 day histology report turnaround and on-demand second opinions from specialists.
  • NHS Pathology Services Surgical pathology reporting service for NHS Trusts, providing histopathology expertise with IT connectivity and NHS LIMS integration via the Health and Social Care Network, currently serving 24 NHS Trusts across the UK.
  • Private Practice Pathology Services
  • AI-Powered Diagnostics (Ibex Galen Prostate) AI-integrated diagnostic workflow using Ibex Medical Analytics' CE-marked Galen Prostate solution for enhanced quality assurance in prostate cancer detection, including primary reporting with AI algorithm review, 24-hour screening services, and discrepancy alerts to pathologists.
  • Diagnostic Audits
  • Whole Slide Imaging Scanning Service

Companies that use LDPath

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

LDPath technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature4 records

LDPath partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Ibex Medical AnalyticscoreTechnology or Integration · 30 June 2020LDPath partnered with Ibex Medical Analytics to integrate AI-powered cancer detection into their digital pathology workflow. This partnership deployed Ibex's CE-Marked Galen Prostate solution, enabling AI algorithm review of prostate biopsies alongside pathologist diagnosis. The integration provides quality assurance with discrepancy alerts and enables 24-hour prostate biopsy screening services. LDPath was the first UK pathology provider to integrate AI into digital pathology workflow.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

LDPath competitors and assessment

Company assessment

Emerging players

  • PathAI: AI-driven pathology platform developing diagnostic and drug-development tools for histopathology. Comparable to LDPath's AI roadmap and a potential competitor for AI-enabled cancer detection contracts with NHS trusts and pharmaceutical sponsors.
  • Ibex Medical Analytics: AI-powered cancer diagnostics developer and LDPath's technology partner for Galen Prostate. Comparable as a pathology-AI specialist; operates in the same clinical workflow with competing AI products that could be deployed by NHS trusts directly, bypassing LDPath.
  • Proscia: Digital pathology software platform enabling AI-powered image analysis and pathology workflows. Comparable to LDPath's digital pathology platform layer; both sell into hospital pathology departments and biopharma, with overlapping AI/digital strategy.
  • Paige: AI-native pathology company with FDA-authorized cancer detection products. Comparable to LDPath in AI-augmented cancer diagnostics and represents a potential competitor for AI procurement deals with NHS trusts and large hospital networks.

Direct peers

  • Diagnexia: Digital pathology platform providing remote histopathology reporting services to NHS trusts and private clients. Direct competitor to LDPath with similar cloud-based slide hosting, specialist pathologist network, and NHS-focused GTM motion.
  • Synlab: Europe's largest medical diagnostics services provider with extensive histopathology capacity. Comparable to LDPath as a multi-country outsourced pathology provider serving both public health systems and private clients with digital workflow integration.
  • Source BioScience: Parent company of LDPath following the 2021 £18.5M acquisition. Provides cellular pathology and genomic services that complement LDPath's digital pathology platform, with overlapping histopathology capabilities and shared customer relationships across NHS and pharmaceutical clients.
  • Unilabs: Major European clinical diagnostics and pathology provider offering histopathology services across multiple countries. Competes with LDPath in outsourced pathology reporting and operates a similar business model combining specialist pathologists with digital workflow.

Broad incumbents

  • Leica Biosystems: Danaher-owned provider of digital pathology hardware, software (Aperio), and laboratory workflow solutions. Comparable to LDPath as an established digital pathology player, though operating more broadly across equipment, reagents, and software.
  • Roche Diagnostics (uPath): Global diagnostics incumbent offering the uPath digital pathology software platform alongside companion diagnostic AI. Comparable as an integrated digital pathology solution competing for the same NHS trust and hospital contracts as LDPath, with deeper R&D and distribution resources.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

LDPath social profiles

Digital presence

LDPath compliance and trust

Trust signal

Compliance6 records

LDPath financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LDPath leadership team

Management profile

Number of profiles

Profiles7 records

LDPath subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

LDPath funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LDPath M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LDPath

What does LDPath do?

LDPath provides digital histopathology reporting services to NHS hospital trusts and private practices, combining whole slide imaging of glass slides with a bespoke Laboratory Information Management System (LIMS) for case tracking and report delivery. The service uses a network of specialist consultant pathologists to deliver rapid 1-2 day histology report turnaround, integrated second opinions, and AI-assisted cancer detection (via the Ibex Galen Prostate partnership) for prostate biopsy diagnosis.

Is LDPath a public or private company?

LDPath is a private company. It is classified as corporate owned and is currently operating.

When was LDPath founded?

LDPath was founded in 2011. It employs 1 to 10 people.

Where is LDPath based?

LDPath is headquartered in London, United Kingdom, in the Europe region.

How does LDPath make money?

Four revenue lines are on record. Histopathology Reporting Services are the primary driver. The others are AI Diagnostic Services, whole Slide Imaging Scanning Services and diagnostic Audits.

Who are LDPath's main competitors?

Emerging players on record are PathAI, Ibex Medical Analytics, Proscia and Paige. Direct peers are Diagnexia, Synlab, Source BioScience and Unilabs. Broad incumbents are Leica Biosystems and Roche Diagnostics (uPath).

Does LDPath have an API?

No public API is recorded for LDPath.

What industry is LDPath in?

LDPath's product category is Digital Pathology Services. Its primary akta.pro industry code is HLAGAFAI, Pathology & Histopathology Services, with a secondary code of HLACAMAB, Anatomic Pathology LIS & Digital Pathology Workflow. Its NAICS code is 621512 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SourcebioscienceSource BioScience completes £18.5m acquisition of LDPath LtdSource BioScience has completed an £18.5 million acquisition of LDPath Ltd to enhance its cellular and digital pathology services. This acquisition positions Source BioScience as the largest private provider of such services in the UK and aims to address the backlog of elective surgeries and improve diagnostic pathways using digital solutions. The combined entity will leverage digital pathology and artificial intelligence to transform service delivery in the sector.PR NewswireBGL Advises SourceBio International plc on Acquisition of LDPath LimitedSourceBio International has completed its strategic acquisition of LDPath Limited, a London-based leader in digital pathology testing services. BGL acted as the exclusive financial advisor for SourceBio on this transaction, which combines their operations to create the UK's largest private provider of cellular and digital pathology services.PR NewswireSource BioScience completes £18.5m strategic acquisition of LDPath Ltd to reimagine the future of pathology by combining cellular and digital pathology platformsSourceBio International agreed to acquire LDPath Limited for £18.5m, combining cellular and digital pathology services. The deal creates the UK's largest private provider of such services, aiming to digitize diagnostic pathways and address NHS backlogs. The combined group plans to seek nationwide-scale contracts and expand further.